Roth Capital analyst Scott Henry upgraded Tonix Pharmaceuticals to Buy from Neutral given that the company is attempting its third shot at the PTSD indication with the RECOVERY trial, enrollment adjustments give the trial a “reasonable shot at success,” the cash runway could get the company to the key PTSD data readout in the first half of 2020, and the stock looks interesting using only a about 20% chance at approval. The analyst also raised his price target on the shares to $4 from 75c.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.